Experimental melanoma vaccine shows promising results

An experimental melanoma vaccine could reduce the risk of the cancer returning or spreading for some high-risk patients. It's personalized for each patient and optimized using artificial intelligence. Dr. Jon LaPook has more details.

US pharmaceutical firms Merck and Moderna announced on Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval. The vaccine, called intismeran autogene, showed “statistically significant and clinically meaningful improvements” for skin cancer

VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results  Reuters

Combining a vaccine and immunotherapy approach could open new ways to treat cancer.

The vaccine candidate pairs an mRNA therapy with the cancer drug Keytruda.